GENLABS, Ltd.

Genlabs began life as a start-up in early 2013 and has since grown to become a leading provider of quality and accurate genetic testing. Using state-of-the-art molecular-genetic methods and a suite of 35 different tests, Genlabs helps patients identify hereditary risks for the development of various congenital and acquired diseases (especially civilisation diseases) as well as various types of food intolerance. The laboratory is a provider of DNA and pharmacogenomics examinations for both patients and clinicians. When the company began a process of expanding its existing medical services and infrastructure, the project received the support of Delta Capital through the creation of the health-care provider Delta Medical Holdings.